^(131)I标记抗人肝癌单克隆抗体人体内照射剂量计算  

Patient Dosimetry for ^(131)I-labeled Anti-HCC mAb(Hepama-1)

作　　者：杨仪[1] 刘增礼[1] 唐军[1] 陆文栋[1] 田金玲[1] 

机构地区：[1]苏州大学附属第二医院核医学科,江苏苏州215004

出　　处：《苏州大学学报（医学版）》2007年第1期114-116,共3页Suzhou University Journal of Medical Science

摘　　要：目的观察131I-抗肝癌细胞单克隆抗体(131I-Hepama-1)的生物学分布情况,估算全身正常器官及肿瘤组织内的照射剂量,评价131I-Hepama-1治疗原发性肝癌的安全性及可行性。方法5例原发性肝癌患者,分别于静脉注射131I-Hepama-1后10min～7d采集全身前、后位图像,获得131I-Hepama-1全身生物学分布情况;利用ROI技术勾画各时相、各器官和肿瘤组织的放射性计数,同时留取患者24h尿样。使用ORIGEN5.0统计软件得到各器官和肿瘤的时间-放射性曲线,分别计算各源器官的累积活度和放射性滞留时间,再由计算内照射剂量软件MIRDOSE3.0得出包括脑、甲状腺、肺、肾、肠道等正常器官及肿瘤组织的内照射吸收剂量。结果5例患者各主要器官和肿瘤的平均内照射吸收剂量分别为:全身0.17Gy,正常肝组织2.06Gy,红骨髓0.07Gy,肺1.91Gy,甲状腺49.55Gy,肿瘤16.18Gy。结论经静脉注射131I-Hepama-1治疗原发性肝癌,肿瘤组织可获得较大的内照射吸收剂量,肝脏和其他脏器的吸收剂量较小,临床使用安全,对于治疗肝细胞肝癌具有一定的价值。Objective To evaluate the biodistribution and the determination of ^131I-labeled anti-HCC mAb（Hepama-1） in patient with hepatocellular carcinoma. Methods Serial whole body scans were acquired up to 7 d after intravenous injection of 1.85 GBq ^131I-Hepama-1 in five patients suffering from hepatocellular carcinoma. Urine was also collected up to 7 d after injection. Radioactivity uptakes were estimated using ROI technique and time-radioactivity curve was obtained with non-linear regression analysis using statistic software. The MIRDOSE 3.0 was applied to calculate the absorbed radiation doses for various organs and tumor. Results The mean absorbed dose was 0. 17 Gy for whole body, 2.06 Gy for the normal liver, 0.07 Gy for the red marrows, 1.91 Gy for the lungs, 49.55 Gy for the thyroid and 16.18 Gy for the tumor. Conclusion The average dosimetry results indicate that the moderate absorbed dose is obtained in the tumor, the therapy is safe, and the method for treating advanced hepatocellular carcinoma is feasible.

关 键 词：肝癌 单克隆抗体 内照射剂量 MIRDOSE3.0 

分 类 号：R735.705[医药卫生—肿瘤]